Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-Cell Lymphoma

Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-Cell Lymphoma

Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) have limited treatment options, particularly if they are transplantation or chimeric antigen receptor (CAR) T-cell ineligible, and novel therapeutics are needed. An 86-year-old woman with relapsed DLBCL received a novel, firs...

Full description

Bibliographic Details
Main Authors: Randeep Sangha, Neal M. Davies, Afshin Namdar, Michael Chu, Jennifer Spratlin, Erwan Beauchamp, Luc G. Berthiaume, John R. Mackey
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Current Oncology
Subjects:
N-myristoyltransferase inhibitors
PCLX-001
non-Hodgkin lymphoma
phase I
first-in-human
dose escalation
Online Access:https://www.mdpi.com/1718-7729/29/3/158

Internet

https://www.mdpi.com/1718-7729/29/3/158

Similar Items